Skip to main content
SpringerLink
Log in

Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview

  • Chapter
  • First Online:
Ovarian Cancer: Molecular & Diagnostic Imaging and Treatment Strategies

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1330))

Abstract

Ovarian cancer (OC) is the most lethal gynecological malignancy among women worldwide. In most cases, it is diagnosed late at an advanced stage and does not respond well to existing therapies leading to its poor prognosis. In addition, other factors including epidemiological, complex histological diversity, multiple molecular alterations, and overlapping signaling pathways are also important contributors to poor disease outcome. Efforts have continued to develop a deeper understanding of the molecular pathogenesis and altered signaling nodes that provide hope for better clinical management through the development of novel approaches for early diagnosis, disease subtyping, prognosis, and therapy. In this chapter, we provide a detailed overview of OC and its histological subtypes and discuss prevalent molecular aberrations and active signaling pathways that drive OC progression. We also summarize various diagnostic and prognostic markers and therapeutic approaches currently being employed and discuss emerging findings that hold the potential to change the future course of OC management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(1), 7–34.

    Google Scholar 

  2. Momenimovahed, Z., et al. (2019). Ovarian cancer in the world: Epidemiology and risk factors. International Journal of Women’s Health, 11, 287–299.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Torre, L. A., et al. (2018). Ovarian cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(4), 284–296.

    Google Scholar 

  4. Reid, B. M., Permuth, J. B., & Sellers, T. A. (2017). Epidemiology of ovarian cancer: A review. Cancer Biology & Medicine, 14(1), 9–32.

    Article  CAS  Google Scholar 

  5. Pokhriyal, R., et al. (2019). Chemotherapy resistance in advanced ovarian cancer patients. Biomarkers in Cancer, 11, 1179299X19860815.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009). The mammalian ovary from genesis to revelation. Endocrine Reviews, 30(6), 624–712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Richards, J. S., & Pangas, S. A. (2010). The ovary: Basic biology and clinical implications. The Journal of Clinical Investigation, 120(4), 963–972.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kurman, R. J., & Shih Ie, M. (2016). The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded. The American Journal of Pathology, 186(4), 733–747.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Chen, V. W., et al. (2003). Pathology and classification of ovarian tumors. Cancer, 97(10 Suppl), 2631–2642.

    Article  PubMed  Google Scholar 

  10. Shaaban, A. M., et al. (2014). Ovarian malignant germ cell tumors: Cellular classification and clinical and imaging features. Radiographics, 34(3), 777–801.

    Article  PubMed  Google Scholar 

  11. Nezhat, F. R., et al. (2015). New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. American Journal of Obstetrics and Gynecology, 213(3), 262–267.

    Article  CAS  PubMed  Google Scholar 

  12. Mabuchi, S., Sugiyama, T., & Kimura, T. (2016). Clear cell carcinoma of the ovary: Molecular insights and future therapeutic perspectives. Journal of Gynecologic Oncology, 27(3), e31.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Koulouris, C. R., & Penson, R. T. (2009). Ovarian stromal and germ cell tumors. Seminars in Oncology, 36(2), 126–136.

    Article  PubMed  Google Scholar 

  14. Fuller, P. J., Leung, D., & Chu, S. (2017). Genetics and genomics of ovarian sex cord-stromal tumors. Clinical Genetics, 91(2), 285–291.

    Article  CAS  PubMed  Google Scholar 

  15. Horta, M., & Cunha, T. M. (2015). Sex cord-stromal tumors of the ovary: A comprehensive review and update for radiologists. Diagnostic and Interventional Radiology, 21(4), 277–286.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Pectasides, D., Pectasides, E., & Kassanos, D. (2008). Germ cell tumors of the ovary. Cancer Treatment Reviews, 34(5), 427–441.

    Article  CAS  PubMed  Google Scholar 

  17. Cossu-Rocca, P., et al. (2006). Chromosome 12p abnormalities in dysgerminoma of the ovary: A FISH analysis. Modern Pathology, 19(4), 611–615.

    Article  CAS  PubMed  Google Scholar 

  18. Hunter, S. M., et al. (2015). Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget, 6(35), 37663–37677.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rojas, V., et al. (2016). Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment. International Journal of Molecular Sciences, 17(12), 2113.

    Article  PubMed Central  CAS  Google Scholar 

  20. Zhang, Y., et al. (2016). TP53 mutations in epithelial ovarian cancer. Translational Cancer Research, 5(6), 650–663.

    Article  CAS  PubMed  Google Scholar 

  21. Cancer Genome Atlas Research Network. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474(7353), 609–615.

    Article  CAS  Google Scholar 

  22. Ricci, F., et al. (2018). Recent insights into mucinous ovarian carcinoma. International Journal of Molecular Sciences, 19(6), 1569.

    Article  PubMed Central  CAS  Google Scholar 

  23. Pennington, K. P., et al. (2014). Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clinical Cancer Research, 20(3), 764–775.

    Article  CAS  PubMed  Google Scholar 

  24. Zweemer, R. P., et al. (1999). Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. Journal of Clinical Pathology, 52(5), 372–375.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tirkkonen, M., et al. (1997). Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Research, 57(7), 1222–1227.

    CAS  PubMed  Google Scholar 

  26. Wysham, W. Z., et al. (2012). BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One, 7(1), e30042.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Anglesio, M. S., et al. (2013). Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. The Journal of Pathology, 229(1), 111–120.

    Article  CAS  PubMed  Google Scholar 

  28. Tan, D. S., et al. (2011). Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clinical Cancer Research, 17(6), 1521–1534.

    Article  CAS  PubMed  Google Scholar 

  29. Despierre, E., et al. (2014). Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. Gynecologic Oncology, 135(3), 415–422.

    Article  CAS  PubMed  Google Scholar 

  30. Kannan, K., et al. (2014). CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma. PLoS Genetics, 10(3), e1004216.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Mahajan, A., et al. (2010). HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Modern Pathology, 23(5), 673–681.

    Article  CAS  PubMed  Google Scholar 

  32. Califano, D., et al. (2014). High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. Journal of Cellular Physiology, 229(1), 53–59.

    CAS  PubMed  Google Scholar 

  33. Pfarr, N., et al. (2017). Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes, Chromosomes & Cancer, 56(10), 758–766.

    Article  CAS  Google Scholar 

  34. Chatterjee, A., Dasgupta, S., & Sidransky, D. (2011). Mitochondrial subversion in cancer. Cancer Prevention Research (Philadelphia, Pa.), 4(5), 638–654.

    Article  CAS  Google Scholar 

  35. Hertweck, K. L., & Dasgupta, S. (2017). The landscape of mtDNA modifications in cancer: A tale of two cities. Frontiers in Oncology, 7, 262.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Petros, J. A., et al. (2005). mtDNA mutations increase tumorigenicity in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 102(3), 719–724.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Dasgupta, S., et al. (2012). Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. Journal of Cellular Physiology, 227(6), 2451–2460.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Liu, V. W., et al. (2001). High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Research, 61(16), 5998–6001.

    CAS  PubMed  Google Scholar 

  39. Van Trappen, P. O., et al. (2007). Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer. Gynecologic Oncology, 104(1), 129–133.

    Article  PubMed  CAS  Google Scholar 

  40. Aikhionbare, F. O., et al. (2007). Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. Journal of Carcinogenesis, 6, 1.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Liu, S., et al. (2016). Identification of sequence nucleotide polymorphisms in the D-loop region of mitochondrial DNA as a risk factor for epithelial ovarian cancer. Mitochondrial DNA. Part A, DNA Mapping, Seqencing, and Analysis, 27(1), 9–11.

    CAS  Google Scholar 

  42. Girolimetti, G., et al. (2017). Mitochondrial DNA sequencing demonstrates clonality of peritoneal implants of borderline ovarian tumors. Molecular Cancer, 16(1), 47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Saldanha, S. N., & Tollefsbol, T. O. (2014). Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. Journal of Cellular Physiology, 229(4), 393–406.

    Article  CAS  PubMed  Google Scholar 

  44. Jimenez, C., et al. (2002). The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. The Journal of Biological Chemistry, 277(44), 41556–41562.

    Article  CAS  PubMed  Google Scholar 

  45. Carnero, A. (2010). The PKB/AKT pathway in cancer. Current Pharmaceutical Design, 16(1), 34–44.

    Article  CAS  PubMed  Google Scholar 

  46. Blanco-Aparicio, C., et al. (2007). PTEN, more than the AKT pathway. Carcinogenesis, 28(7), 1379–1386.

    Article  CAS  PubMed  Google Scholar 

  47. Meng, Q., et al. (2006). Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cellular Signalling, 18(12), 2262–2271.

    Article  CAS  PubMed  Google Scholar 

  48. Roy, L., & Cowden Dahl, K. D. (2018). Can stemness and chemoresistance be therapeutically targeted via signaling pathways in ovarian cancer? Cancers (Basel), 10(8), 241.

    Article  CAS  Google Scholar 

  49. Luo, X., et al. (2013). Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Proliferation, 46(4), 436–446.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Ali, A. Y., et al. (2015). Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Molecular Carcinogenesis, 54(11), 1301–1314.

    Article  CAS  PubMed  Google Scholar 

  51. Mabuchi, S., Hisamatsu, T., & Kimura, T. (2011). Targeting mTOR signaling pathway in ovarian cancer. Current Medicinal Chemistry, 18(19), 2960–2968.

    Article  CAS  PubMed  Google Scholar 

  52. Dobbin, Z. C., & Landen, C. N. (2013). The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. International Journal of Molecular Sciences, 14(4), 8213–8227.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Wen, W., et al. (2014). Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Molecular Cancer Therapeutics, 13(12), 3037–3048.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Hedvat, M., et al. (2009). The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell, 16(6), 487–497.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Saini, U., et al. (2018). STAT3/PIAS3 levels serve as “early signature” genes in the development of high-grade serous carcinoma from the fallopian tube. Cancer Research, 78(7), 1739–1750.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Rosen, D. G., et al. (2006). The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer, 107(11), 2730–2740.

    Article  CAS  PubMed  Google Scholar 

  57. Burgos-Ojeda, D., et al. (2015). CD24+ ovarian cancer cells are enriched for cancer-initiating cells and dependent on JAK2 signaling for growth and metastasis. Molecular Cancer Therapeutics, 14(7), 1717–1727.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Koul, H. K., Pal, M., & Koul, S. (2013). Role of p38 MAP kinase signal transduction in solid tumors. Genes & Cancer, 4(9–10), 342–359.

    Article  CAS  Google Scholar 

  59. Mane, S. M., et al. (1990). RAS gene activation in acute myelogenous leukemia: Analysis by in vitro amplification and DNA base sequence determination. Genes, Chromosomes & Cancer, 2(1), 71–77.

    Article  CAS  Google Scholar 

  60. Edkins, S., et al. (2006). Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biology & Therapy, 5(8), 928–932.

    Article  CAS  Google Scholar 

  61. Harris, T. J., & McCormick, F. (2010). The molecular pathology of cancer. Nature Reviews. Clinical Oncology, 7(5), 251–265.

    Article  CAS  PubMed  Google Scholar 

  62. Li, H. T., et al. (2011). KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer. Oncology Reports, 25(6), 1691–1697.

    CAS  PubMed  Google Scholar 

  63. Vereczkey, I., et al. (2011). Molecular characterization of 103 ovarian serous and mucinous tumors. Pathology Oncology Research, 17(3), 551–559.

    Article  CAS  PubMed  Google Scholar 

  64. Stewart, C. J., et al. (2012). KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: Association with concurrent endometriosis. Human Pathology, 43(8), 1177–1183.

    Article  CAS  PubMed  Google Scholar 

  65. Vacca, F., et al. (2000). Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Research, 60(18), 5310–5317.

    CAS  PubMed  Google Scholar 

  66. Venkatakrishnan, G., Salgia, R., & Groopman, J. E. (2000). Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. The Journal of Biological Chemistry, 275(10), 6868–6875.

    Article  CAS  PubMed  Google Scholar 

  67. Choi, K. C., Auersperg, N., & Leung, P. C. (2003). Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium. Reproductive Biology and Endocrinology, 1, 71.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Aster, J. C., Pear, W. S., & Blacklow, S. C. (2017). The varied roles of Notch in cancer. Annual Review of Pathology, 12, 245–275.

    Article  CAS  PubMed  Google Scholar 

  69. Tan, D. S., Agarwal, R., & Kaye, S. B. (2006). Mechanisms of transcoelomic metastasis in ovarian cancer. The Lancet Oncology, 7(11), 925–934.

    Article  PubMed  Google Scholar 

  70. Groeneweg, J. W., et al. (2014). Notch signaling in serous ovarian cancer. Journal of Ovarian Research, 7, 95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Schreck, K. C., et al. (2010). The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: A potential mechanism of therapeutic resistance. Clinical Cancer Research, 16(24), 6060–6070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Yamaguchi, E., et al. (2002). Expression of Notch ligands, Jagged1, 2 and Delta1 in antigen presenting cells in mice. Immunology Letters, 81(1), 59–64.

    Article  CAS  PubMed  Google Scholar 

  73. Sasaki, Y., et al. (2002). The p53 family member genes are involved in the Notch signal pathway. The Journal of Biological Chemistry, 277(1), 719–724.

    Article  CAS  PubMed  Google Scholar 

  74. McAuliffe, S. M., et al. (2012). Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences of the United States of America, 109(43), E2939–E2948.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Harrington, B. S., & Annunziata, C. M. (2019). NF-kappaB signaling in ovarian cancer. Cancers (Basel), 11(8), 1182.

    Article  CAS  Google Scholar 

  76. Rose, S. L., et al. (2010). Notch 1 signaling is active in ovarian cancer. Gynecologic Oncology, 117(1), 130–133.

    Article  CAS  PubMed  Google Scholar 

  77. Hopfer, O., et al. (2005). The Notch pathway in ovarian carcinomas and adenomas. British Journal of Cancer, 93(6), 709–718.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Aburjania, Z., et al. (2018). The role of Notch3 in cancer. The Oncologist, 23(8), 900–911.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Shih, V. F., et al. (2011). A single NFkappaB system for both canonical and non-canonical signaling. Cell Research, 21(1), 86–102.

    Article  CAS  PubMed  Google Scholar 

  80. Kleinschmidt, E. G., et al. (2019). Rgnef promotes ovarian tumor progression and confers protection from oxidative stress. Oncogene, 38(36), 6323–6337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Momeny, M., et al. (2018). Blockade of nuclear factor-kappaB (NF-kappaB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells. The International Journal of Biochemistry & Cell Biology, 99, 1–9.

    Article  CAS  Google Scholar 

  82. House, C. D., et al. (2017). NFkappaB promotes ovarian tumorigenesis via classical pathways that support proliferative cancer cells and alternative pathways that support ALDH(+) cancer stem-like cells. Cancer Research, 77(24), 6927–6940.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Wilson, A. J., et al. (2013). Tracking NF-kappaB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. Journal of Ovarian Research, 6(1), 63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Coticchia, C. M., Yang, J., & Moses, M. A. (2008). Ovarian cancer biomarkers: Current options and future promise. Journal of the National Comprehensive Cancer Network, 6(8), 795–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Ueland, F. R. (2017). A perspective on ovarian cancer biomarkers: Past, present and yet-to-come. Diagnostics (Basel), 7(1), 14.

    Article  CAS  Google Scholar 

  86. Khoo, S. K., & MacKay, E. V. (1976). Carcinoembryonic antigen (CEA) in ovarian cancer: Factors influencing its incidence and changes which occur in response to cytotoxic drugs. British Journal of Obstetrics and Gynaecology, 83(10), 753–759.

    Article  CAS  PubMed  Google Scholar 

  87. Bettegowda, C., et al. (2014). Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine, 6(224), 224ra24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Schwarzenbach, H., Hoon, D. S., & Pantel, K. (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews. Cancer, 11(6), 426–437.

    Article  CAS  PubMed  Google Scholar 

  89. Kamat, A. A., et al. (2010). Plasma cell-free DNA in ovarian cancer: An independent prognostic biomarker. Cancer, 116(8), 1918–1925.

    Article  CAS  PubMed  Google Scholar 

  90. Wimberger, P., et al. (2011). Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. International Journal of Cancer, 128(11), 2572–2580.

    Article  CAS  PubMed  Google Scholar 

  91. Campos, C. D. M., et al. (2018). Molecular profiling of liquid biopsy samples for precision medicine. Cancer Journal, 24(2), 93–103.

    Article  CAS  PubMed  Google Scholar 

  92. du Bois, A., et al. (2005). 2004 Consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of Oncology, 16(Suppl 8), viii7–viii12.

    Article  PubMed  Google Scholar 

  93. Harter, P., et al. (2007). Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. International Journal of Gynecological Cancer, 17(6), 1238–1244.

    Article  CAS  PubMed  Google Scholar 

  94. du Bois, A., et al. (2010). Potential role of lymphadenectomy in advanced ovarian cancer: A combined exploratory analysis of three prospectively randomized phase III multicenter trials. Journal of Clinical Oncology, 28(10), 1733–1739.

    Article  PubMed  Google Scholar 

  95. Harter, P., et al. (2019). A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. The New England Journal of Medicine, 380(9), 822–832.

    Article  PubMed  Google Scholar 

  96. Cortez, A. J., et al. (2018). Advances in ovarian cancer therapy. Cancer Chemotherapy and Pharmacology, 81(1), 17–38.

    Article  CAS  PubMed  Google Scholar 

  97. Dasari, S., & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology, 740, 364–378.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Gligorov, J., & Lotz, J. P. (2004). Preclinical pharmacology of the taxanes: Implications of the differences. The Oncologist, 9(Suppl 2), 3–8.

    Article  CAS  PubMed  Google Scholar 

  99. Helm, C. W., & States, J. C. (2009). Enhancing the efficacy of cisplatin in ovarian cancer treatment—Could arsenic have a role. Journal of Ovarian Research, 2, 2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Lou, J. Y., et al. (2006). [Reversal of multi-drug resistance in ovarian cancer cell by RNA interference]. Zhonghua Fu Chan Ke Za Zhi, 41(6): 413–416.

    Google Scholar 

  101. Goto, T., et al. (2006). Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncology Reports, 15(5), 1265–1271.

    CAS  PubMed  Google Scholar 

  102. de Queiroz, R. M., et al. (2016). Changes in O-linked N-acetylglucosamine (O-GlcNAc) homeostasis activate the p53 pathway in ovarian cancer cells. The Journal of Biological Chemistry, 291(36), 18897–18914.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Collinet, P., et al. (2006). In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice. The Journal of Obstetrics and Gynaecology Research, 32(5), 449–453.

    Article  CAS  PubMed  Google Scholar 

  104. Kigawa, J., et al. (2002). Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells. Gynecologic Oncology, 84(2), 210–215.

    Article  CAS  PubMed  Google Scholar 

  105. Miettinen, S., & Ylikomi, T. (2009). Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy. Anti-Cancer Drugs, 20(7), 589–600.

    Article  CAS  PubMed  Google Scholar 

  106. Leijen, S., et al. (2016). Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. Journal of Clinical Oncology, 34(36), 4354–4361.

    Article  CAS  PubMed  Google Scholar 

  107. Parkes, E. E., & Kennedy, R. D. (2016). Clinical application of poly(ADP-ribose) polymerase inhibitors in high-grade serous ovarian cancer. The Oncologist, 21(5), 586–593.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Lord, C. J., & Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. Science, 355(6330), 1152–1158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Rocha, C. R. R., et al. (2018). DNA repair pathways and cisplatin resistance: An intimate relationship. Clinics (Sao Paulo), 73(Suppl 1), e478s.

    Article  Google Scholar 

  110. Swisher, E. M., et al. (2017). Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial. The Lancet Oncology, 18(1), 75–87.

    Article  CAS  PubMed  Google Scholar 

  111. Navarro, S. A., et al. (2016). Cancer suicide gene therapy: A patent review. Expert Opinion on Therapeutic Patents, 26(9), 1095–1104.

    Article  CAS  PubMed  Google Scholar 

  112. Rawlinson, J. W., et al. (2013). Adenoviral-delivered HE4-HSV-tk sensitizes ovarian cancer cells to ganciclovir. Gene Therapy and Molecular Biology, 15, 120–130.

    PubMed  Google Scholar 

  113. Sher, Y. P., et al. (2013). Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth. Oncogene, 32(9), 1082–1090.

    Article  CAS  PubMed  Google Scholar 

  114. Singh, P. P., et al. (2011). Purine nucleoside phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer. BMC Cancer, 11, 368.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Nishida, N., et al. (2006). Angiogenesis in cancer. Vascular Health and Risk Management, 2(3), 213–219.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Bekes, I., et al. (2016). Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? Molecular Cancer, 15, 13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  117. Welch, S. A., et al. (2010). Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer, 20(5), 787–793.

    Article  PubMed  Google Scholar 

  118. Xu, L., et al. (2000). Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. International Journal of Oncology, 16(3), 445–454.

    CAS  PubMed  Google Scholar 

  119. Byrne, A. T., et al. (2003). Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clinical Cancer Research, 9(15), 5721–5728.

    CAS  PubMed  Google Scholar 

  120. Husain, A., et al. (2016). Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer. Gynecologic Oncology, 142(3), 465–470.

    Article  CAS  PubMed  Google Scholar 

  121. Aghajanian, C., et al. (2015). Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology, 139(1), 10–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Matulonis, U. A., et al. (2009). Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. Journal of Clinical Oncology, 27(33), 5601–5606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Patel, G. K., et al. (2019). Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Scientific Reports, 9(1), 5335.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Kannan, A., et al. (2017). Genetic mutation and exosome signature of human papilloma virus associated oropharyngeal cancer. Scientific Reports, 7, 46102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Philley, J. V., et al. (2017). Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease. Oncotarget, 8(11), 18070–18081.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Nakamura, K., et al. (2017). Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Molecular Cancer Research, 15(1), 78–92.

    Article  CAS  PubMed  Google Scholar 

  127. Shender, V. O., et al. (2014). Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Molecular & Cellular Proteomics, 13(12), 3558–3571.

    Article  CAS  Google Scholar 

  128. Dorayappan, K. D. P., et al. (2016). The biological significance and clinical applications of exosomes in ovarian cancer. Gynecologic Oncology, 142(1), 199–205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Srivastava, S. K., et al. (2017). MicroRNAs in gynecological cancers: Small molecules with big implications. Cancer Letters, 407, 123–138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Kobayashi, M., et al. (2014). Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. Journal of Translational Medicine, 12, 4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  131. Vaksman, O., et al. (2014). Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis, 35(9), 2113–2120.

    Article  CAS  PubMed  Google Scholar 

  132. He, L., et al. (2019). Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics, 9(26), 8206–8220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Tang, M. K. S., et al. (2018). Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. Nature Communications, 9(1), 2270.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Trajkovic, K., et al. (2008). Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science, 319(5867), 1244–1247.

    Article  CAS  PubMed  Google Scholar 

  135. Pelosi, G., et al. (2012). DeltaNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: A novel two-hit, sparing-material approach. Journal of Thoracic Oncology, 7(2), 281–290.

    Article  PubMed  Google Scholar 

  136. Chalmin, F., et al. (2010). Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. The Journal of Clinical Investigation, 120(2), 457–471.

    CAS  PubMed  PubMed Central  Google Scholar 

  137. Ostrowski, M., et al. (2010). Rab27a and Rab27b control different steps of the exosome secretion pathway. Nature Cell Biology, 12(1), 19–30.

    Article  CAS  PubMed  Google Scholar 

  138. Sun, D., et al. (2010). A novel nanoparticle drug delivery system: The anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Molecular Therapy, 18(9), 1606–1614.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Tian, Y., et al. (2014). Doxorubicin-loaded magnetic silk fibroin nanoparticles for targeted therapy of multidrug-resistant cancer. Advanced Materials, 26(43), 7393–7398.

    Article  CAS  PubMed  Google Scholar 

  140. Johnsen, K. B., et al. (2014). A comprehensive overview of exosomes as drug delivery vehicles—Endogenous nanocarriers for targeted cancer therapy. Biochimica et Biophysica Acta, 1846(1), 75–87.

    CAS  PubMed  Google Scholar 

  141. Escudier, B., et al. (2005). Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase I clinical trial. Journal of Translational Medicine, 3(1), 10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  142. Dai, S., et al. (2008). Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Molecular Therapy, 16(4), 782–790.

    Article  CAS  PubMed  Google Scholar 

  143. Morse, M. A., et al. (2005). A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. Journal of Translational Medicine, 3(1), 9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  144. Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell, 161(2), 205–214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Sharma, P., et al. (2011). Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nature Reviews. Cancer, 11(11), 805–812.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Hamanishi, J., et al. (2015). Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. Journal of Clinical Oncology, 33(34), 4015–4022.

    Article  CAS  PubMed  Google Scholar 

  147. Konstantinopoulos, P. A., et al. (2019). Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncology, 5(8), 1141–1149.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Yan, W., Hu, H., & Tang, B. (2019). Advances of chimeric antigen receptor T cell therapy in ovarian cancer. Oncotargets and Therapy, 12, 8015–8022.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Chekmasova, A. A., et al. (2010). Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clinical Cancer Research, 16(14), 3594–3606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Yeung, T. L., et al. (2019). Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer. Clinical Cancer Research, 25(21), 6417–6428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Crawford, A., et al. (2019). A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Science Translational Medicine, 11(497), eaau7534.

    Article  PubMed  CAS  Google Scholar 

  152. Dou, J., et al. (2009). Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model. Immunobiology, 214(6), 483–492.

    Article  CAS  PubMed  Google Scholar 

  153. Yu, Y., et al. (2008). rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunology, 21(4), 435–442.

    Article  CAS  PubMed  Google Scholar 

  154. Nersesian, S., et al. (2019). Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer. Frontiers in Immunology, 10, 1782.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Olusola, P., et al. (2019). Human papilloma virus-associated cervical cancer and health disparities. Cell, 8(6), 622.

    Article  CAS  Google Scholar 

Download references

Author Contributions

O.M., S.K.S., and S.D. wrote the manuscript; S.D., S.S., R.P.R., and A.P.S. proofread and corrected it; O.M. prepared figures; A.P.S. conceptualized the idea, provided resources, and supervised the project. All authors read and approved the final manuscript.

Funding: Authors would like to acknowledge the funding from NIH/NCI [R01CA175772, R01CA224306, U01CA185490 (to A.P.S.); R01CA204801, R01CA231925 (to S.S.)] and USAMCI.

Author information

Authors and Affiliations

  1. Department of Pathology, College of Medicine, University of South Alabama, Mobile, AL, USA

    Orlandric Miree, Sanjeev Kumar Srivastava, Seema Singh & Ajay Pratap Singh

  2. Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

    Orlandric Miree, Sanjeev Kumar Srivastava, Seema Singh & Ajay Pratap Singh

  3. Department of Medicine, The University of Texas Health Science Center at Tyler, Tyler, TX, USA

    Santanu Dasgupta

  4. Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, USA

    Seema Singh & Ajay Pratap Singh

  5. Division of Gynecologic Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

    Rodney Rocconi

Authors
  1. Orlandric Miree
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanjeev Kumar Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Santanu Dasgupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seema Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rodney Rocconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ajay Pratap Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ajay Pratap Singh .

Editor information

Editors and Affiliations

  1. Dept. Veterinary Pathobiology, University of Missouri-Columbia Dept. Veterinary Pathobiology, COLUMBIA, MO, USA

    Heide Schatten

Ethics declarations

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Miree, O., Srivastava, S.K., Dasgupta, S., Singh, S., Rocconi, R., Singh, A.P. (2021). Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview. In: Schatten, H. (eds) Ovarian Cancer: Molecular & Diagnostic Imaging and Treatment Strategies. Advances in Experimental Medicine and Biology, vol 1330. Springer, Cham. https://doi.org/10.1007/978-3-030-73359-9_1

Download citation

Publish with us

Policies and ethics

Search

Navigation